Top View
- Thrombopoietin Receptor Agonist Therapy in Primary Immune
- FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models
- Variant Histology, Igd and CD30 Expression in Low Risk Pediatric Nodular Lymphocyte Predominant Hodgkin Lymphoma: a Report from the Children’S Oncology Group
- First-In-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Þ Follicular and Other CD20 Non-Hodgkin Lymphomas a C Ajay K
- Prognostic Value of Novel Immune-Related Genomic
- RANKL Structural and Functional Insights Of
- Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti-PD1-Resistant Lung Tumor Model
- ADCETRIS Safely and Effectively
- Increased Expression of Costimulatory Markers CD134 and CD80 On
- The CD137 Ligand Is Important for Type 1 Diabetes Development But
- Serum B-Cell Maturation Antigen: a Novel Biomarker to Predict Outcomes for Multiple Myeloma Patients
- Anti B-Cell Maturation Antigen CAR T-Cell and Antibody Drug Conjugate Therapy for Heavily Pre-Treated Relapsed and Refractory Multiple Myeloma
- Antibodies and Derivatives Targeting DR4 and DR5 for Cancer Therapy
- Signal Transduction by Tumour Necrosis Factor and Tumour Necrosis Factor Related Ligands and Their Receptors
- The TRAIL Apoptotic Pathway in Cancer Onset, Progression and Therapy
- Pulmonary Macrophage Transplantation Therapy
- RANK Monoclonal Antibody (64C1385.1)
- Prognostic Significance of Serum Soluble DR5 Levels in Small-Cell Lung Cancer Zhenfa Wan1,#, Xiaoshan Zhang2,#, Xinshuang Yu3, Yong Hou3,
- Melanoma Subpopulations That Rapidly Escape MAPK Pathway Inhibition Incur DNA Damage and Rely on Stress Signalling
- Identification of Six Hub Genes and Analysis of Their Correlation with Drug Sensitivity in Acute Myeloid Leukemia Through Bioinformatics
- Thrombocytopenia and Hemostatic Changes in Acute and Chronic Liver Disease: Pathophysiology, Clinical and Laboratory Features, and Management
- New Insights Into Apoptosis Signaling by Apo2l/TRAIL
- Osteoclast Precursors in Murine Bone Marrow Express CD27 and Are Impeded in Osteoclast Development by CD70 on Activated Immune Cells
- Ligand Expression Signals Regulate CD30
- Strong and Selective Glomerular Localization of CD134 Ligand and TNF Receptor-1 in Proliferative Lupus Nephritis
- Fas Receptor Is Required for Estrogen Deficiency-Induced Bone Loss in Mice
- Thymic Epithelial Cell Development Response to RANKL Promotes Medullary Production in Β IRF7-Dependent IFN
- Targeting Death-Inducing Receptors in Cancer Therapy
- 4-1BB (CD137) Signals Depend Upon CD28 Signals in Alloimmune Responses
- Infected Macrophages Engage Alveolar Epithelium to Metabolically Reprogram Myeloid Cells and Promote Antibacterial Inflammation
- TNF Receptor and Ligand Superfamilies
- Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor T Cell
- Agonists of the TRAIL Death Receptor DR5 Sensitize Intestinal Stem Cells
- Epha2/CD137 Bicycle® Tumor-Targeted Immune Cell
- CD30 Characterizes Polylobated Lymphocytes and Disease
- A Frameshift in CSF2RB Predominant Among Ashkenazi Jews Increases Risk for Crohn's Disease and Reduces Monocyte Signaling Via GMCSF
- Monoclonal Antibody to RANK (CD265/ODFR
- Platelet Aggregation Response in Immune Thrombocytopenia Patients Treated with Romiplostim
- An Immunosuppressive Dendritic Cell Subset Accumulates at Secondary Sites and Promotes Metastasis in Pancreatic Cancer
- Two Patterns of Thrombopoietin Signaling Suggest No Coupling Between Platelet Production and Thrombopoietin Reactivity in Thrombocytopenia-Absent Radii Syndrome
- YIPF2 Promotes Chemotherapeutic Agent-Mediated Apoptosis Via
- Open Full Page
- RANKL Structural and Functional Insights Of
- Role of Fas and RANKL Signaling in Peripheral Immune Tolerance
- Regulation of Breast Cancer Cell Proliferation by APRIL
- PD-1 Blockade and CD27 Stimulation Activate Distinct Transcriptional Programs That Synergize for Cd8þ T-Cell–Driven Antitumor Immunity Sarah L
- Understanding CD30 Biology and Therapeutic Targeting: a Historical Perspective Providing Insight Into Future Directions